Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Director departure
|
|
OMNI BIO PHARMACEUTICAL, INC. (OMBP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/24/2015 |
8-K
| Form 8-K - Current report |
| 05/07/2015 |
8-K
| Other Events |
| 03/13/2015 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Even... |
| 02/02/2015 |
8-K
| Other Events, Financial Statements and Exhibits |
| 01/07/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/20/2014 |
8-K
| Other Events |
| 09/11/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 08/14/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Employment Agreement dated August 6, 2014, between Omni Bio Pharmaceutical, Inc. and Jack Riccardi",
"Omni Bio Appoints Jack Riccardi as Chief Financial Officer Fort Collins, CO, August 14, 2014 – Omni Bio Pharmaceutical, Inc. , an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today the appointment of Jack Riccardi as its Chief Financial Officer. Mr. Riccardi brings more than 30 years of financial leadership experience. He was formerly CFO of ADial Pharmaceuticals and served most recently as CFO and Partner at Green Street Ventures. Mr. Riccardi’s appointment will become effective on September 1, 2014. Bruce Schneider, Ph.D., Chief Executive Officer of Omni Bio, commented, “As Omni Bio continues to evolve its business, we are very pleased to add such a seasoned financial leader to our team. Jack has a proven ..." |
|
| 06/02/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 04/29/2014 |
8-K
| Entry into a Material Definitive Agreement |
| 04/25/2014 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/07/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/06/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/26/2013 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 11/06/2013 |
8-K
| Form 8-K - Current report |
| 07/17/2013 |
8-K
| Appointed a new director |
| 02/12/2013 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 10/05/2012 |
8-K
| Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce... |
| 10/02/2012 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 08/27/2012 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/27/2012 |
8-K
| Form 8-K - Current report |
| 06/12/2012 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 06/04/2012 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 05/24/2012 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 04/04/2012 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 03/20/2012 |
8-K
| Form 8-K - Current report |
| 01/17/2012 |
8-K
| Form 8-K - Current report |
| 01/13/2012 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 12/22/2011 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Patent Issued for Treatment of Diabetes. Omni Bio Pharmaceutical, Inc. Obtains Patent for Diabetes Treatment Through Licensing Partner, Bio Holding, Inc. Denver, CO, December 22, 2011 - Omni Bio Pharmaceutical, Inc. previously announced on December 8, 2011 that U.S. Patent No. 8,071,551, entitled “METHODS AND COMPOSITIONS FOR TREATING DIABETES,” was issued by the United States Patent and Trademark Office on December 6, 2011 . The Diabetes Patent expires in May 2022. The Diabetes Patent relates to methods for treating diabetes by administering Alpha-1 antitrypsin or a derivative of AAT. AAT is an FDA-approved drug currently prescribed for chronic lung disease in AAT-deficient patients. Omni Bio licenses the Diabetes Patent under an agreement with a private company, Bio Holding, Inc. that w..." |
|
| 12/08/2011 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Patent Issued for Treatment of Diabetes Denver, Colorado based Omni Bio Pharmaceutical, Inc. confirms announcement from U.S. Patent Office. Denver, CO, December 8, 2011 - Omni Bio Pharmaceutical, Inc. today announced that U.S. Patent No. 8,071,551, entitled “METHODS AND COMPOSITIONS FOR TREATING DIABETES,” was issued by the United States Patent and Trademark Office on December 6, 2011 . The Diabetes Patent expires in May 2022. The Diabetes Patent is the most recently issued patent that Omni Bio licenses under agreements with the University of Colorado Denver and a private company. The Diabetes Patent claims a method for treating diabetes in subjects by administering an effective amount of a composition comprising Alpha-1 antitrypsin or a derivative of AAT. AAT is an FDA-approved drug curr..." |
|
| 08/12/2011 |
8-K
| Form 8-K - Current report |
| 08/01/2011 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/21/2011 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Departure of Directors or Cer...|
Docs:
|
"Stockholders' Agreement by and among BioMimetix Pharmaceutical, Inc., Omni Bio Pharmaceutical, Inc. and the other investors, collectively, (the “Stockholders”)",
"Stock Purchase Agreement by and between BioMimetix Pharmaceutical, Inc. and Omni Bio Pharmaceutical, Inc.",
"Warrant issued to Omni Bio Pharmaceutical, Inc. or its permitted assigns to purchase shares of common stock in BioMimetix Pharmaceutical, Inc.",
"Letter of employment by and between James Crapo and Omni Bio Pharmaceutical, Inc.",
"Omni Bio Acquires 25% of BioMimetix Pharmaceutical for $2,000,000 Leading Academic Medical Center Executes Exclusive Licensing Agreement with BioMimetix to Develop New Class of Patented Compounds to Treat Radiation Toxicity" |
|
| 06/28/2011 |
8-K
| Form 8-K - Current report |
|
|
|